

TABLE OF CONTENTS

December 7, 2009

No. 2167

BUSINESS

- 1 Astellas Aims at Well-Balanced Growth in 4 Regions: Mr Nogimori
- Pursuing Alliances to Enrich Product Portfolio
- Agensys Expands ADC Collaboration with Seattle Genetics
- Citizen Petition Withdrawn Regarding Prograf in US
- 3 Price Maintenance System Essential to Promote Drug Industry: Mr Nagayama
- 4 Japan Should Establish National Vaccine Plan: Mr Feliciano
- 4 Diovan Back to Top Place on GP Market: Rep Track Survey
- 6 Dutch Industry-Academia Alliances for Bio-Based Innovation Highlighted
- 6 **BUSINESS NEWS IN BRIEF**
- Pfizer, Astellas Launch Caduet Combination Tablets
- Abbott Acquires Global Rights to Biologic Pain Killer from PanGenetics
- Sanofi-aventis, Regeneron Expand Strategic Antibody Collaboration
- Alfresa Pharma to Expand Contract Manufacturing Business
- Pharma Industry to Become a Major Foreign Cashcow: Dr Sakurai of DPJ

REGULATORY

- 8 Market Price Survey Finds Mean *Yakkasa* of 8.4%
- 8 Japan's 1st GLP-1 Analogue Victoza Recommended for Approval
- Japan's 1st Combinations of ARB + Ca Blockers Recommended for Approval
- 10 Afinitor, Abraxan Recommended for Approval
- 10 *Chuikyo* to Decide on Industry Proposed Drug Pricing System Reform by Year-End
- 11 Cut Total Medical Fees by 3%: MOF
- *Koroshō* Insists on Net Increase
- 12 Over 100 DPJ Legislators Get Together Calling for Increases in Medical Fees
- 12 **REGULATORY NEWS IN BRIEF**
- Takeda Applies for Prevention of Ulcers due to NSAIDs for Takepron
- Glufast Approved in China: Kissei
- Abilify Approved for Irritability in Children with Autistic Disorders in US
- Eisai Applies for Aricept Extended-Release Tablets in US
- Silodosin Recommended for Approval in EU: Kissei

- AnGes Agrees with FDA on SPA for PIII Trial of Collatogene
- Otsuka Withdraws Application for Abilify for Major Depression in Europe
- Tsumura to File NDA for *Daikenchuto* in US in 2016
- US GLs Recommend Effient for ACS Patients Following PCI

GENERICS

- 15 Biosimilar of EPO Recommended for Approval
- 15 Larger Differences in Prices Necessary between Original Drugs and Generics
- Too Many Generics for Single Original Drug

R&D

- 16 Amgen to File NDA for AMG531 in Early 2010
- 16 **R&D NEWS IN BRIEF**
- Janssen Signs Clinical Research Aid Agreement with Keio Univ.
- Sub-Analysis Shows Greater Efficacy for Ticagrelor over Clopidogrel: AZ
- Roche's GLYT-1 Inhibitor Improves Negative Symptoms of Schizophrenia
- *Koroshō* to Create Team to Discuss How to Promote Development of Cutting-Edge Technology

TOPICS

- 17 **TOPICS**
- Nouvelle Place Begins Senior Contract MRs Dispatching Business

SELF-MEDICATION

- 18 Switch OTC Recommended for Loxoprofen
- Epinastine Also to Become Available as OTC Drug
- 18 Ketotifen Nasal Drops Reclassified as Class 2 OTC Drug

OPINION

- 20 **OPINION**
- How Marketing Moves in Mysterious Ways: Philip Carrigan

MEDICAL FACILITIES & NURSING CARE

- 22 Blue Letter Required for Nexavar
- Distribution of Blue Letter Started
- 22 Effectively Use DB for Pharmacovigilance: Dr Chan
- 23 Many Patients with Depression Need Treatment for Pain: Dr Shimodera